Avalo Therapeutics, Inc. Common Stock

AVTX XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

730M

Short interest (May 15)

11.9%

Net Short (Jun 03 ): 0.0%

Borrow Fee

0.53%

↓ 44.3%

Available Shares

↓ 8.7%

Price Chart

Company Overview

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001534120

Asset Type: CS

Market Data

Market Cap: $733,815,385

Employees: 33

Status: Active

Short Interest

Current Borrow Fee 0.53%

Range: 0.53% - 0.53%

Available Shares 3M

Range: 1.9M - 2.5M

Recent Changes

Fee Change: ↑ 2.1%

Available Change: ↑ 4.2%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime